Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 127

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 127
---
 D.3. to our consolidated financial statements, included at Item 18. of this annual report), mainly in increasing capacity and improving productivity at our various production and R&D sites. Our principal acquisitions, capital expenditures and divestitures in 2022 , 2023 and 2024 are described in Notes D.1. & D.2. (“Changes in the scope of consolidation”), D.3. (“Property, plant and equipment”) and D.4. (“Goodwill and other intangible assets”) to our consolidated financial statements, included at Item 18. of this annual report. For associated commitments, and in particular future contingent milestone payments, refer to Notes D.18 and D.21. to our consolidated financial statements, which provide disclosures about liabilities related to business combinations and our principal research and development collaboration agreements, respectively. As of December 31, 2024 , our firm commitments in respect of future capital expenditures amounted to € 422 million. The principal locations involved are: for medicines, the industrial facilities at Frankfurt (Germany); Le Trait, Maisons-Alfort, Compiègne, and Ambares (France); Cambridge (United States); Geel (Belgium); Origgio, Anagni, Brindisi and Scoppito (Italy); and for vaccines, the facilities at Swiftwater (United States); Toronto (Canada); Marcy-l’Étoile, Neuville-sur-Saône and Val-de- Reuil (France); and Singapore. In the medium term and assuming no changes in the scope of consolidation, we expect to invest on average approximately €1.5 billion a year in property, plant and equipment. We believe that our own cash resources and the undrawn portion of our existing credit facilities will be sufficient to fund these expenditures. Our principal ongoing capital expenditures are described below. Medicines Our Medicines industrial operations are organized through end-to-end clusters. We have four dedicated biotechnology hubs: Paris/Lyon (France), Frankfurt (Germany), Geel (Belgium) and the Boston Area (United States). Exploiting innovative techniques, including cell and microbiological culture and the development of viral vectors, our biotechnology operations call for highly specific knowledge and expertise backed by dedicated production platforms to support global product launches. In May 2024, Sanofi announced plans for major investment to increase the production capabilities of our facility at Vitry-sur-Seine (France). We also have end-to-end clusters with chemistry, pharmaceutical and injectable sites organized through a network